Benefits of 2 CAR T-cell Therapies May Justify Their High Price, ICER Report Argues – Lymphoma News Today
Lymphoma News Today |
Benefits of 2 CAR T-cell Therapies May Justify Their High Price, ICER Report Argues
Lymphoma News Today Two CAR T-cell therapies are now FDA-approved, Yescarta (axicabtagene ciloleucel) for people with advanced large B-cell lymphoma, and Kymriah (tisagenlecleucel) to treat children and young adults with advanced B-cell acute lymphoblastic leukemia … |
